直肠癌放疗中注射水凝胶间隔物保护性器官的可行性初步研究
这项初步研究在两名接受新辅助放化疗的直肠癌患者中,评估可注射、可吸收、不透射线水凝胶间隔物植入的可行性及其对性器官的保护剂量学获益。间隔物植入可行且耐受良好;男性性器官剂量获益极小,女性阴道剂量显著降低,两种方案平均降低超过5 Gy。作者认为,对于器官保留方案和部分有性生活的女性患者,可考虑使用水凝胶间隔物使性器官避开高放疗剂量。
要点
- 直肠癌新辅助放化疗前在直肠与前列腺/阴道间植入水凝胶间隔物可行且耐受良好。
- 女性阴道剂量显著降低,两种方案平均降低超过5 Gy;男性性器官剂量获益极小。
- 作者认为,对器官保留方案和部分有性生活的女性患者,可考虑使用水凝胶间隔物保护性器官。
核心结论
- 对于器官保留方案和部分有性生活的女性患者,可考虑使用水凝胶间隔物使性器官避开高放疗剂量。
- 对于晚期直肠肿瘤女性,新辅助放化疗前在直肠与阴道之间植入间隔物可行,并降低阴道剂量。
研究设计与样本
- 初步研究(可行性初步研究),纳入两名接受新辅助放化疗的直肠癌患者(一男一女)。
- 在新辅助放化疗和根治性手术前,于直肠与阴道/前列腺之间植入可注射、可吸收、不透射线水凝胶间隔物。
- 注射前后行CT扫描,并对比标准方案(45/50 Gy)与剂量递增方案(46/55.2 Gy)进行剂量学比较研究。
关键影像表现/征象
- 两名患者的间隔物分别植入直肠-前列腺间隙或直肠-阴道间隙,均可行且耐受良好。
- 男性患者使用间隔物对性器官的剂量学获益极小。
- 女性患者使用间隔物后阴道受照剂量显著降低,两种方案平均降低超过5 Gy。
临床应用与阅片要点
- 作者认为,对于器官保留方案和部分有性生活的女性患者,可考虑使用水凝胶间隔物保护性器官。
- 作者指出,对于晚期直肠肿瘤女性,新辅助放化疗前在直肠与阴道之间植入间隔物可行,并降低阴道剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this pilot study was to investigate in two rectal cancer patients undergoing neoadjuvant chemo-radiotherapy (nCRT) the implant feasibility and dosimetric benefit in sexual organ-sparing of an injectable, absorbable, radiopaque hydrogel spacer.
METHODS: Two rectal cancer patients (one male and one female) underwent hydrogel implant between rectum and vagina/prostate before nCRT and curative surgery. A CT scan was performed before and after injection and a comparative dosimetric study was performed testing a standard (45/50 Gy) and a dose escalated (46/55.2 Gy) schedule.
RESULTS: In both patients, the spacer implant in the recto-prostatic or recto-vaginal space was feasible and well tolerated. For the male, the dosimetric benefit with spacer was minimal for sexual organs. For the female however, doses delivered to the vagina were significantly reduced with spacer with a mean reduction of more than 5 Gy for both regimens.
CONCLUSIONS: For organ preservation protocols and selected sexually active female patients, use of hydrogel spacers can be considered to spare sexual organs from the high radiotherapy dose levels.
ADVANCES IN KNOWLEDGE: For females with advanced rectal tumor, a spacer implant between the rectum and the vagina before nCRT is feasible and reduces doses delivered to the vagina.
引用
- Achard V, Ris F, Rouzaud M, et al. Sexual organ-sparing with hydrogel spacer injections for rectal cancer radiotherapy: a feasibility pilot study. Br J Radiol. 2021. PMID: 33481641. doi:10.1259/bjr.20200931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。